Table 1.
Comparison of clinical and laboratory features between ZNF300 hypermethylated and non-hypermethylated MDS patients.
| Patient’s features | Non-hypermethylated (n = 48) | Hypermethylated (n = 22) | P value |
|---|---|---|---|
| Sex (male/female) | 26/22 | 13/9 | 0.798 |
| Median age, years (range) | 57.5 (27-84) | 69 (28–86) | 0.271 |
| Median WBC, ×109/L (range) | 3.0 (1.1–44.4) | 2.5 (0.6–82.4) | 0.240 |
| Median hemoglobin, g/L (range) | 65 (35–140) | 62 (43–107) | 0.889 |
| Median platelets, ×109/L (range) | 69 (0–1176) | 50 (10–323) | 0.475 |
| Median BM blasts, % (range) | 5 (0–19) | 6 (0–18) | 0.229 |
| WHO classifications | 0.840 | ||
| RCUD/RARS | 5 | 2 | |
| RCMD/RCMD-RS | 18 | 8 | |
| RAEB-1 | 8 | 3 | |
| RAEB-2 | 14 | 9 | |
| MDS with isolated del(5q) | 3 | 0 | |
| IPSS scores | 0.806 | ||
| Low | 7 | 2 | |
| Int-1 | 23 | 9 | |
| Int-2 | 7 | 5 | |
| High | 7 | 3 | |
| No data | 4 | 3 | |
| Gene mutations | |||
| CEBPA (+ /−) | 2/41 | 0/19 | 1.000 |
| IDH1/2 (+/−) | 2/41 | 0/19 | 1.000 |
| DNMT3A (+/−) | 0/43 | 1/18 | 0.306 |
| U2AF1 (+/−) | 2/41 | 4/15 | 0.066 |
| SRSF2 (+/−) | 0/43 | 2/17 | 0.090 |
| SF3B1 (+/−) | 4/39 | 0/19 | 0.303 |
| SETBP1 (+/−) | 1/42 | 0/19 | 1.000 |
MDS myelodysplastic syndromes, WBC white blood cells, BM bone marrow, WHO World Health Organization, IPSS International Prognostic Scoring System.